Detalle Publicación

Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis

Autores: Ferreira, J. P.; Machu, J. L.; Girerd, N. ; Jaisser, F. ; Thum, T. ; Butler, J. ; González Miqueo, Aránzazu; Díez Martínez, Domingo Francisco Javier; Heymans, S. ; McDonald, K.; Gyöngyösi, M.; Firat, H. ; Rossignol, P. ; Pizard, A. ; Zannad, F. (Autor de correspondencia)
Título de la revista: ESC HEAR FAILURE
ISSN: 2055-5822
Volumen: 5
Número: 1
Páginas: 139-148
Fecha de publicación: 2018
AIMS: Myocardial fibrosis alters the cardiac architecture favouring the development of cardiac dysfunction, including arrhythmias and heart failure. Reducing myocardial fibrosis may improve outcomes through the targeted diagnosis and treatment of emerging fibrotic pathways. The European-Commission-funded 'FIBROTARGETS' is a multinational academic and industrial consortium with the main aims of (i) characterizing novel key mechanistic pathways involved in the metabolism of fibrillary collagen that may serve as biotargets, (ii) evaluating the potential anti-fibrotic properties of novel or repurposed molecules interfering with the newly identified biotargets, and (iii) characterizing bioprofiles based on distinct mechanistic phenotypes involving the aforementioned biotargets. These pathways will be explored by performing a systematic and collaborative search for mechanisms and targets of myocardial fibrosis. These mechanisms will then be translated into individualized diagnostic tools and specific therapeutic pharmacological options for heart failure. METHODS AND RESULTS: The FIBROTARGETS consortium has merged data from 12 patient cohorts in a common database available to individual consortium partners. The database consists of >12 000 patients with a large spectrum of cardiovascular clinical phenotypes. It integrates community-based population cohorts, cardiovascular risk cohorts, and heart failure cohorts. CONCLUSIONS: The FIBROTARGETS biomarker programme is aimed at exploring fibrotic pathways allowing the bioprofiling of patients into specific 'fibrotic' phenotypes and identifying new therapeutic targets that will potentially enable the development of novel and tailored anti-fibrotic therapies for heart failure.